Israel’s SpliSense (see here previously) has begun a first Phase 1/2 human trial of its SPL84 treatment for a specific genetic mutation that causes cystic fibrosis. SpliSense utilizes proprietary RNA therapies called ASOs (antisense oligonucleotides) to correct mutations.

https://www.prnewswire.com/news-releases/splisense-initiates-phase-12-study-of-spl84-rna-based-therapy-for-the-treatment-of-cystic-fibrosis-301702837.html